Central Bank & Trust Co. Has $947,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Central Bank & Trust Co. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% during the first quarter, Holdings Channel reports. The fund owned 5,713 shares of the company’s stock after selling 268 shares during the quarter. Central Bank & Trust Co.’s holdings in Johnson & Johnson were worth $947,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $29,000. Conquis Financial LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $155.02 on Monday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a fifty day simple moving average of $153.59 and a 200 day simple moving average of $153.67. The company has a market cap of $372.99 billion, a P/E ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. Johnson & Johnson’s dividend payout ratio is 57.84%.

Wall Street Analyst Weigh In

Several research firms have weighed in on JNJ. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.